Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Stemedica and The Scripps Research Institute to Jointly Investigate the Therapeutic Effect of Ischemia Tolerant Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis  

 
 
December 21, 2012 - (Stemedica) - "Stemedica Cell Technologies, Inc., a leading manufacturer of adult ischemia tolerant allogeneic stem cells and stem cell factors announced that the Company has signed an agreement with The Scripps Research Institute to investigate the role of Stemedica's ischemia tolerant human mesenchymal stem cells and stem cell factors as a therapy for severe lung injury and sepsis."
Read Full Article

 

Posted on 9-Jan-13 by Toto, Brent
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: